In a crossover trial of adults with HNF1A-MODY on glucose-lowering drugs (18 of 19 completed), 4 weeks of add-on empagliflozin lowered mean CGM glucose by 2.3 mmol/L vs placebo, with no significant difference in hypoglycaemia.
RCTn = 19
Maagensen et al. Empagliflozin in HNF1A-MODY (MODY3): A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial